,address1,address2,city,state,zip,country,phone,fax,longBusinessSummary,fullTimeEmployees,companyOfficers,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,beta,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,sharesOutstanding,bookValue,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,lastSplitFactor,lastSplitDate,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,returnOnAssets,freeCashflow,operatingCashflow,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,750 Battery Street,Suite 330,San Francisco,CA,94111,United States,415 283 2200,415 283 2201,"VIA Pharmaceuticals, Inc., a development stage biotechnology company, focuses on the development of compounds for the treatment of cardiovascular and metabolic diseases. It is developing a pipeline of small molecule drugs that target the underlying causes of cardiovascular and metabolic diseases, including vascular inflammation, high cholesterol, high triglycerides, and insulin sensitization/diabetes. The company's drug development pipeline includes VIA-3196, a Phase-1 ready liver-directed thyroid hormone receptor (THR) beta agonist that targets dyslipidemia, such as high LDL cholesterol, high triglycerides, and elevated Lp(a); Diacylglycerol Acyl Transferase 1 (DGAT1) inhibitor, which is in pre-clinical development stage treatment of type 2 diabetes with upside potential in weight control and dyslipidemia; and VIA-2291, a 5-Lipoxygenase inhibitor that has completed third Phase 2 clinical trial for the treatment of atherosclerotic plaque, an underlying cause of heart attack, stroke, and other vascular diseases. VIA Pharmaceuticals, Inc. has two research, development, and commercialization agreements with Hoffman-LaRoche Inc. and Hoffman-LaRoche Ltd. for THR beta agonist; and multiple compounds from preclinical DGAT1 metabolic disorders program. The company was founded in 2004 and is headquartered in San Francisco, California.",6,"{'maxAge': 1, 'name': 'Dr. Thomas  Quertermous FACC, M.D.', 'age': 70, 'title': 'Chief Scientific Officer & Member of Scientific Advisory Board', 'yearBorn': 1952, 'exercisedValue': 0, 'unexercisedValue': 0}",86400,4,1e-06,1e-06,1e-06,1e-06,1e-06,1e-06,1e-06,1e-06,-0.213716,50,50,11242,8681,8681,0.0,0.0,0,0,20,1e-06,1e-06,1e-06,1e-06,0.0,0.0,USD,13917421,0.0,20558400,-0.9,1293753600,1325289600,1293753600,-9601315,-0.471,1:15,1181088000,-2.383,PNK,EQUITY,VIAP,VIAP,VIA PHARMACEUTICALS INC,"VIA Pharmaceuticals, Inc.",1181136600,America/New_York,EDT,-14400000,1e-06,5.0,5.0,5.0,5.0,none,1,84001,0.004,-5839100,14001397,0.004,0.023,-2.41895,-3620254,-6106270,0.0,0.0,0.0,USD,
